-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $52

Benzinga·11/04/2026 15:15:05
Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $57 to $52.